|
Casi Pharmaceuticals inc (NASDAQ: CASI) |
|
Casi Pharmaceuticals inc
CASI's Fundamental analysis
Select the Comparisons :
|
|
Select the Ratio:
|
|
|
Casi Pharmaceuticals Inc 's sales fell
by -21.41 % in IV. Quarter 2023 from the same quarter a year ago.
Ranking at No. 2791
Major Pharmaceutical Preparations industry recorded
deterioration of revenues by -4.85 %
Casi Pharmaceuticals Inc net loss decreased from $-40 millions, to $-26 millions in IV. Quarter 2023,
• More on CASI's Growth
|
|
Casi Pharmaceuticals Inc realized a net loss in trailing twelve months.
Casi Pharmaceuticals Inc realized cash reduction of $ -2.25 per share in trailing twelve-month period. |
Company |
- |
PE TTM
|
Industry |
- |
PE TTM
|
|
Company's Price to Sales ratio is at 1.01.
Major Pharmaceutical Preparations industry's Price to Sales ratio is at 5.44.
• More on CASI's Valuation
|
|
|
|
|
Casi Pharmaceuticals Inc realized net loss in trailing twelve months.
Casi Pharmaceuticals Inc realized cash outflow of $ -2.25per share in trailing twelve-month period. |
Company |
- |
PE TTM
|
Industry |
- |
PE TTM
|
|
Company's Price to Sales ratio is at 1.01.
Major Pharmaceutical Preparations industry's Price to Sales ratio is at 5.44.
Casi Pharmaceuticals Inc Price to Book Ratio is at 1.41 lower than Industry Avg. of 84.23. and higher than S&P 500 Avg. of 0.01
• More on CASI's Valuation
|
|
|
|
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.
Copyright © 2025 CSIMarket, Inc. All rights
reserved.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com